CARsgen Therapeutics 2025 Investor Day

Positive Clinical Data for Allogeneic CAR-T Products CT0596 and CT1190B

2025 ESMO | Adjuvant Therapy with Claudin18.2-specific CAR T Cells (Satri-cel) in High-Risk Pancreatic Cancer (CT041-ST-05)

2025 IMS | Long Term Follow-up of Zevor-cel in Patients with Relapsed/Refractory Multiple Myeloma

2025 EHA | A phase I study of GPRC5D targeting CAR T-cell therapy CT071 for high-risk newly diagnosed multiple myeloma

2025 ASCO | Claudin18.2-specific CAR T cells (Satri-cel) versus treatment of physician’s choice (TPC) for previously treated advanced gastric or gastroesophageal junction cancer (G/GEJC): Primary results from a randomized, open-label, phase II trial (CT041-ST-01)